Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report

Table 4

(a) Result of clinical response. (b) Baseline diagnosis of patients who were assessed in the clinical response.

(a)

	𝑛	Cycles (𝑛)	PR 𝑛 (%)	SD 𝑛 (%)	PD 𝑛 (%)	ORR 𝑛 (%)
DAC	8	2	0 (0)	4 (50)	4 (50)	4 (50)
	3	4	0 (0)	1 (33.33)	2 (66.67)	1 (33.33)
	3*	6	1 (50)	0 (0)	1 (50)	1 (50)
DAC + chemo	18	2	1 (5.6)	12 (66.7)	5 (27.8)	13 (72.3)
	11	4	2 (18.2)	4 (36.4)	5 (45.5)	6 (54.5)
	11	6	2 (18.2)	5 (45.5)	4 (36.4)	7 (63.6)
DAC + CIK	5	2	0 (0)	4 (80)	1 (20)	4 (80)
	5	4	0 (0)	4 (80)	1 (20)	4 (80)
	5	6	0 (0)	4 (80)	1 (20)	4 (80)

Note. Data is 𝑛 (%). CIK: cytokine induced killer cells; DAC + chemo: decitabine in combination with chemotherapy; DAC + CIK: decitabine in combination with CIK; PR: partial response; SD: stable disease; PD: progressive disease; ORR: objective response rate. Tumors were assessed every 2 cycles by using RECIST 1.0; RECIST: the Response Evaluation Criteria in Solid Tumors; ∗one patient discontinued treatment attributable to digestive tract hemorrhage.

(b)

	Partial response	Stable disease	Progressive disease
DAC	Malignant pleural tumor	Colorectal adenocarcinoma; Esophageal adenocarcinoma	Alveolar carcinoma; Intrahepatic bile ducts adenocarcinoma; Hepatocellular carcinoma; Gastric cancer
DAC + chemo	Ovary carcinoma; Lung adenocarcinoma	Tubal serous adenocarcinoma; Lung adenocarcinoma; Cardia adenocarcinoma; Hodgkin’s lymphoma; Non-Hodgkin's lymphoma	Cervical squamous cell carcinomas; Lung adenocarcinoma; Small cell carcinoma of the esophagus; Esophageal squamous cell carcinomas; Colon adenocarcinoma; Non-Hodgkin's lymphoma
DAC + CIK	—	Pancreatic cancer; Hepatocellular carcinoma	Hepatocellular carcinoma

Note. CIK: cytokine induced killer cells; DAC + chemo: decitabine in combination with chemotherapy; DAC + CIK: decitabine in combination with CIK.